Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeDropped

Termination of the oral testosterone product option agreement with テソアールエックス社

First written in FY2027-H1. 1 of 1 entries say "Dropped", first in FY2027-H1. Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Termination of Option Agreement with TesoRx for Oral Testosterone ProductA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1DroppedAnnual report

    「あすか製薬株式会社 テソアールエックス社 United States Oral testosterone product Grant of an option for development and sales rights in Japan and Southeast Asian countries The earlier of the date on which the option was not exercised after December 2016 or the date on which a license agreement was signed」

    The option agreement for development and sales rights in Japan and Southeast Asian countries for the oral testosterone product was disclosed for the first time as a material agreement that had ended.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.